Seeking Alpha Market Currents 4/19/13 Canaccord says "the CF corrector discovery platform" has been validated and the "likelihood for trial success and uptake" has increased. Canaccord raises target to $96
Article: Helping the DEA With Arena Pharmaceuticals' Belviq's Final Scheduling
By: Chris Roberts Seeking Alpha
1) The drug has marginal efficacy, and will be used in combination with phentarmine
2) The drug is like LSD, and will be abused in the same manner.
3) The drug is addictive, and patient population (obese people) have a proclivity to addictions.
4) The drug will be used in large quantities to achieve a "high".
looks good folks.
looks like VVUS about to takeoff here. bought yesterday and added more later in the day.